Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

PURPOSE: Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities. PATIENTS AND METHODS: We conducted a multicenter phase II trial of imatinib in metastatic mucosal, acral, or chronically sun-damaged (CSD) melanoma with KIT amplifications and/o...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Hodi, F. Stephen, Corless, Christopher L., Giobbie-Hurder, Anita, Fletcher, Jonathan A., Zhu, Meijun, Marino-Enriquez, Adrian, Friedlander, Philip, Gonzalez, Rene, Weber, Jeffrey S., Gajewski, Thomas F., O'Day, Steven J., Kim, Kevin B., Lawrence, Donald, Flaherty, Keith T., Luke, Jason J., Collichio, Frances A., Ernstoff, Marc S., Heinrich, Michael C., Beadling, Carol, Zukotynski, Katherine A., Yap, Jeffrey T., Van den Abbeele, Annick D., Demetri, George D., Fisher, David E.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2013
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878082/
https://ncbi.nlm.nih.gov/pubmed/23775962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.7836
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker